This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

21 Drugs Facing FDA Approval Decisions

Amylin Pharmaceuticals (AMLN), Alkermes and Eli Lilly (LLY)

Drug/indication:Bydureon for diabetes

Approval decision date:Oct. 22, 2010

Recent stock performance: At just over $20 a share, Amylin is up 43% for the year.

This is the second FDA review cycle for Bydureon, a once-weekly injectable drug for diabetes.


Vivus (VVUS - Get Report)

Drug/indication: Qnexa for obesity

Approval decision date: October 28, 2010

Recent stock performance: At $5.61, Vivus' value was cut in half by the negative FDA advisory panel vote.

The odds in favor of Qnexa's approval took a big hit in July when an FDA advisory panel voted against the drug's approval due to a lack of long-term safety data. Vivus is expected to announce results from a two-year safety study of Qnexa in the third quarter.


Biodel (BIOD)

Drug/indication: VIAject for diabetes

Approval decision date: Oct. 29, 2010

Recent stock performance: Closed Friday at $3.88. The stock has traded as low as $3.22 and as high as $6.25 this year.

VIAject is a fast-acting insulin analogue designed for absorption into the bloodstream faster than currently marketed rapid-acting insulins.

4 of 7

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
CADX $0.00 0.00%
AMGN $163.58 0.00%
BMY $65.35 0.00%
CPIX $6.99 0.00%
OREX $7.54 0.00%

Markets

DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs